<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, M.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Chen, C.</style></author><author><style face="normal" font="default" size="100%">Cibeira, M.T.</style></author><author><style face="normal" font="default" size="100%">Attal, M.</style></author><author><style face="normal" font="default" size="100%">Spencer, A.</style></author><author><style face="normal" font="default" size="100%">Rajkumar, S.V.</style></author><author><style face="normal" font="default" size="100%">Yu, Z.</style></author><author><style face="normal" font="default" size="100%">Olesnyckyj, M.</style></author><author><style face="normal" font="default" size="100%">Zeldis, J.B.</style></author><author><style face="normal" font="default" size="100%">Knight, R.D.</style></author><author><style face="normal" font="default" size="100%">Weber, D.M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure</style></title><secondary-title><style face="normal" font="default" size="100%">Blood</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-58149384555&amp;doi=10.1182%2fblood-2008-02-141614&amp;partnerID=40&amp;md5=b94ea16243cf4e7a5e64d3436981dc2a</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">112</style></volume><pages><style face="normal" font="default" size="100%">4445 - 4451</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">This analysis assessed the efficacy and safety of lenalidomide + dexamethasone in patients with relapsed or refractory multiple myeloma (MM) previously treated with thalidomide. Of 704 patients, 39% were thalidomide exposed. Thalidomide-exposed patients had more prior lines of therapy and longer duration of myeloma than thalidomide-naive patients. Lenalidomide + dexamethasone led to higher overall response rate (ORR), longer time to progression (TTP), and progression-free survival (PFS) versus placebo + dexamethasone despite prior thalidomide exposure. Among lenalidomide + dexamethasone-treated patients, ORR was higher in thalidomide-naive versus thalidomide-exposed patients (P = .04), with longer median TTP (P = .04) and PFS (P = .02). Likewise for dexamethasone alone-treated patients (P = .03 for ORR, P = .03 for TTP, P = .06 for PFS). Prior thalidomide did not affect survival in lenalidomide + dexamethasone-treated patients (36.1 vs 33.3 months, P &gt; .05). Thalidomide-naive and thalidomide-exposed patients had similar toxicities. Lenalidomide + dexamethasone resulted in higher rates of venous thromboembolism, myelosuppression, and infections versus placebo + dexamethasone, independent of prior thalidomide exposure. Lenalidomide + dexamethasone was superior to placebo + dexamethasone, independent of prior thalidomide exposure. Although prior thalidomide may have contributed to inferior TTP and PFS compared with thalidomide-naive patients, these parameters remained superior compared with placebo + dexamethasone; similar benefits compared with placebo + dexamethasone were not evident for thalidomide-exposed patients in terms of overall survival. Studies were registered at http://www.clinicaltrials. gov under NCT00056160 and NCT00424047. © 2008 by The American Society of Hematology.</style></abstract><issue><style face="normal" font="default" size="100%">12</style></issue><notes><style face="normal" font="default" size="100%">Cited By :139Export Date: 21 February 2017</style></notes></record></records></xml>